Login to Your Account

In The Clinic NEWS
'Important shift,' post-Sanofi

Shares of Zealand Pharma A/S (NASDAQ:ZEAL) popped 10 percent, closing Tuesday at $16.13 for a gain of $1.52, after the first multinational phase III trial of the company's lead candidate, dasiglucagon, met with success in treating severe hypoglycemia.

Non-proliferative diabetic retinopathy

Like drugmakers are apt to do, Regeneron Pharmaceuticals Inc. is looking upstream of its current indications to capture additional patients for its anti-VEGF eye drug, Eylea (aflibercept), but not every analyst is convinced an additional indication will result in sustainably increased sales.

'Best-case scenario'

Heron Therapeutics Inc. hit a home run in dual phase III trials examining its non-opioid candidate, HTX-011, to control postoperative pain in patients following bunionectomy and hernia repair. Top-line data showed that HTX-011 achieved its primary and key secondary endpoints, producing statistically significant reductions in both pain intensity and need for opioids through 72 hours post-surgery compared both to placebo and to bupivacaine solution, the current standard of care. Importantly, fewer patients who received HTX-011 reported severe pain at any post-op time point, and more who received HTX-011 were opioid-free through 72 hours past surgery.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: